[Update from France Macula Federation: Treatment of Wet AMD]

J Fr Ophtalmol. 2018 Nov;41(9):862-867. doi: 10.1016/j.jfo.2018.06.002. Epub 2018 Oct 22.
[Article in French]


Purpose: To update the recommendations of the France Macula Federation for treatment of wet age-related macular degeneration (AMD).

Methods: Analysis of literature and expert opinion.

Results: The FFM recommends initiating anti-VEGF therapy as soon as possible after diagnosis of exudative AMD. There has been no major change in the last several years concerning the procedure of intravitreal injection itself. However, the litigious points are discussed: simultaneous bilateral injection; antibiotic therapy; medico-legal aspects. All anti-VEGF strategies possess advantages and limitations. The strategy should be left to the ophthalmologists' preference. However, the chosen strategy should be explained to patients and strictly followed.

Conclusion: The treatment of wet-AMD is more precisely codified than before. However, various strategies still coexist.

Keywords: Aflibercept; Anti-VEGF; Bevacizumab; DMLA exsudative; Ranibizumab; Wet AMD.

Publication types

  • Practice Guideline

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Anti-Bacterial Agents / administration & dosage
  • Bevacizumab / administration & dosage
  • Expert Testimony
  • France
  • Humans
  • Intravitreal Injections
  • Macula Lutea / pathology
  • Ophthalmology / organization & administration
  • Ophthalmology / standards
  • Ranibizumab / administration & dosage
  • Societies, Medical / organization & administration
  • Societies, Medical / standards
  • Wet Macular Degeneration / pathology
  • Wet Macular Degeneration / therapy*


  • Angiogenesis Inhibitors
  • Anti-Bacterial Agents
  • Bevacizumab
  • Ranibizumab